BI 1910 is a monoclonal antibody designed to target and block the Tumor Necrosis Factor Receptor 2 (TNFR2). This receptor is often found on the surface of certain cancer cells and can help them grow and survive. By blocking TNFR2, BI 1910 aims to stop the growth of these cancer cells and potentially shrink tumors. This medication is being tested both on its own and in combination with another drug to see how well it works and how safe it is for patients with advanced solid tumors.

Pembrolizumab is a type of cancer treatment known as an immune checkpoint inhibitor. It works by helping the body’s immune system recognize and attack cancer cells. Pembrolizumab blocks a specific protein on the surface of immune cells, which can prevent them from attacking cancer cells. By blocking this protein, pembrolizumab allows the immune system to better target and destroy cancer cells. In this trial, it is being used in combination with BI 1910 to see if the two drugs together can more effectively treat advanced solid tumors.

Advanced Solid Tumors – Advanced solid tumors refer to a group of cancers that originate in solid organs or tissues and have progressed to a more severe stage. These tumors can occur in various parts of the body, such as the lungs, liver, pancreas, or colon. As they advance, they may grow larger, invade nearby tissues, and potentially spread to other parts of the body through the bloodstream or lymphatic system. The progression of these tumors often leads to increased symptoms, which can include pain, fatigue, and organ dysfunction, depending on the tumor’s location. The complexity of advanced solid tumors often requires a comprehensive approach to management and care.